Anna Fialová

ORCID: 0000-0003-1436-5142
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • Immune cells in cancer
  • CAR-T cell therapy research
  • Head and Neck Cancer Studies
  • Vector-borne infectious diseases
  • T-cell and B-cell Immunology
  • Viral Infections and Vectors
  • Ovarian cancer diagnosis and treatment
  • Monoclonal and Polyclonal Antibodies Research
  • Nanoplatforms for cancer theranostics
  • Glycosylation and Glycoproteins Research
  • Lung Cancer Research Studies
  • Vector-Borne Animal Diseases
  • Cutaneous Melanoma Detection and Management
  • Education, Psychology, and Social Research
  • Herpesvirus Infections and Treatments
  • Colorectal and Anal Carcinomas
  • Colorectal Cancer Treatments and Studies
  • Melanoma and MAPK Pathways
  • Prostate Cancer Treatment and Research
  • Chronic Lymphocytic Leukemia Research
  • Cutaneous lymphoproliferative disorders research
  • Mosquito-borne diseases and control

Sotio (Czechia)
2013-2024

Charles University
2010-2020

University Hospital Kralovske Vinohrady
2016-2020

University of Hradec Králové
2015

University Hospital in Motol
2010-2014

In-Q-Tel
2012

Czech Academy of Sciences, Biology Centre
2010

Institute of Parasitology
2010

Immunogenic cell death is characterized by the early surface exposure of chaperones including calreticulin and HSPs, which affect dendritic (DC) maturation uptake presentation tumor antigens. It has also been shown that it late release high mobility group box 1 (HMGB1), acts through Toll-like receptor 4 (TLR4) augments antigens from dying cells to DCs. Most data on immunogenic were obtained using mouse models. In this study, we investigated capacity clinically used chemotherapeutics induce...

10.1158/0008-5472.can-11-0950 article EN Cancer Research 2011-05-21

Human papillomavirus (HPV) infection is one of the most important etiologic causes oropharyngeal head and neck squamous cell carcinoma (HNSCC). Patients with HPV-positive HNSCC were reported to have a better clinical outcome than patients HPV-negative cancers. However, little known about possible different outcomes. In this study, we analyzed detailed immune profile tumor samples from respect their HPV status. We characteristics infiltrates, including frequency distribution...

10.4161/21624011.2014.965570 article EN OncoImmunology 2014-10-29

Abstract Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients cancer, reflecting their contribution to the development tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates varying degrees organization and maturation. Specifically, mature TLSs (mTLS) as forming only 16% HGSOCs relatively elevated tumor mutational burden (TMB) are an increased...

10.1038/s41467-024-46873-w article EN cc-by Nature Communications 2024-03-21

Recent studies have identified molecular events characteristic of immunogenic cell death (ICD), including surface exposure calreticulin (CRT), the heat shock proteins HSP70 and HSP90, release high‐mobility group box protein 1 (HMGB1) ATP from dying cells. We investigated potential high hydrostatic pressure (HHP) to induce ICD in human tumor HHP induced rapid expression HSP70, HSP90 CRT on surface. also HMGB1 ATP. The interaction dendritic cells (DCs) with HHP‐treated led a more rate DC...

10.1002/ijc.28766 article EN International Journal of Cancer 2014-02-05

<h3>Background</h3> Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rates in OPSCC patients. Therefore, a better stratification patients and the development novel therapeutic protocols are crucially needed. The importance tumor-infiltrating B cells (TIL-Bs) shaping antitumor immunity remains unclear; therefore, we analyzed frequency,...

10.1186/s40425-019-0726-6 article EN cc-by Journal for ImmunoTherapy of Cancer 2019-10-17

In multiple oncological settings, expression of the coinhibitory ligand PD-L1 by malignant cells and tumor infiltration immune expressing receptors such as PD-1, CTLA4, LAG-3, or TIM-3 conveys prognostic predictive information. Conversely, impact these features microenvironment on disease outcome among high-grade serous carcinoma (HGSC) patients remains controversial.We harnessed a retrospective cohort 80 chemotherapy-naïve HGSC to investigate CD8+ T cells, CD20+ B DC-LAMP+ dendritic well...

10.1158/1078-0432.ccr-18-4175 article EN Clinical Cancer Research 2019-05-11

Abstract The type of immune cells that are present within the tumor microenvironment can play a crucial role in survival patients. However, little is known about dynamics tumor‐infiltrating during disease progression. We studied infiltrated tissues ovarian cancer patients at different stages disease. early development carcinomas were characterized by strong Th17 response, whereas stage II patients, recruitment high numbers Th1 was observed. In disseminated tumors (Stages III–IV), we detected...

10.1002/ijc.27759 article EN International Journal of Cancer 2012-08-03

Toxoplasma gondii, a parasite infecting 20-60% of humans in various countries, influences the behaviour infected animal and human hosts.Infected subjects have changes several Cattell's Cloninger's personality factors.Recently, three independent studies shown that Rh-positive are protected against T. gondii-induced reaction times increased risk traffic accidents.Here we searched for evidence similar effects RhD phenotype on toxoplasmosis-or aging-associated profile about 302 blood donors.We...

10.14411/fp.2010.018 article EN Folia Parasitologica 2010-06-01

In order to select a suitable combination of cancer cell lines as an appropriate source antigens for dendritic cell-based immunotherapy ovarian cancer, we analyzed the expression level 21 tumor associated (BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, WT1) in 4 established and primary cells isolated from high-grade serous epithelial tissue. More than 90% samples expressed very high...

10.18632/oncotarget.10028 article EN Oncotarget 2016-06-14

The current trends in the education of individuals with special educational needs (= SEN) include their inclusion ordinary life, i.e. also into mainstream system. Within inclusion, there is a "fusion" so-called minority (i.e. Individuals disabilities / needs) and majority intact population peers). Based on data gathered so far context this research related to pupils Czech Republic primary schools (n= 500), we can say that negative attitude prevails teachers executive workers relation SEN. It...

10.1016/j.sbspro.2015.01.196 article EN Procedia - Social and Behavioral Sciences 2015-01-01

Novel immunotherapy modalities significantly improve survival of patients with metastatic melanoma. However, CTLA-4-blocking monoclonal antibody ipilimumab is effective only in a small proportion patients. Biomarkers for prediction treatment response are indispensably needed.To determine the utility multimarker detection circulating melanoma cells as prognostic and pharmacodynamic biomarker treated ipilimumab.Patients (n = 62) unresectable stage III or IV were recruited prospectively. The...

10.1111/jdv.13940 article EN Journal of the European Academy of Dermatology and Venereology 2016-08-24

Lung cancer is the leading cause of mortality worldwide; therefore, understanding biological or clinical role tumor-associated antigens and autoantibodies eminent interest for designing antitumor immunotherapeutic strategies.Here we prospectively analyzed serum frequencies New York esophageal squamous cell carcinoma 1 (NY-ESO-1), human epidermal growth factor 2/neu, melanoma-associated antigen A4 (MAGE-A4) antibodies expression corresponding in tumors 121 patients with NSCLC undergoing an...

10.1016/j.jtho.2016.09.136 article EN publisher-specific-oa Journal of Thoracic Oncology 2016-10-25
Coming Soon ...